TG Therapeutics shares have risen 15.1% since its second-quarter earnings report, outperforming the S&P 500. The company reported earnings of 5 cents per share, missing the Zacks Consensus Estimate of 41 cents, but total revenues of $240.3 million beat estimates and rose 70.3% year over year, driven by strong sales of its drug Briumvi. Management raised its 2026 total revenue guidance to around $950 million from $925 million, and narrowed U.S. Briumvi net product sales guidance to $890-$905 million. However, estimates have trended downward over the past month, and the stock holds a Zacks Rank #3 (Hold).
TG Therapeutics IncQ2 earnings beat with strong Briumvi sales and raised 2026 revenue guidance
Alnylam Pharmaceuticals Inc